Last reviewed · How we verify

NCT05589922

The Relationship Between Abnormal Modified Schober Index and Demographic Characteristics and Clinical Variables

Completed Last updated 12 June 2023
What this trial tests

trial in Ankylosing Spondylitis in 100 participants. Completed in 30 January 2023.

Timeline
24 October 2022
Primary endpoint
18 November 2022
30 January 2023

Quick facts

Lead sponsorMustafa Kemal University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment100
Start date24 October 2022
Primary completion18 November 2022
Estimated completion30 January 2023
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Mustafa Kemal University

Who can join

18 and older, any sex, with Ankylosing Spondylitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will aim to compare ankylosing spondylitis (AS) participants with abnormal modified Schober index (AMSI) versus AS participants with normal modified Schober index (NMSI) in pain, morning stiffness, balance, kinesiophobia and the fear of falling. In addition, the investigators will aim to determine which demographic characteristics and variables predispose AMSI to occur

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Ankylosing Spondylitis

Currently open trials in the same condition.

Other Mustafa Kemal University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05589922.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing